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A Combination of Nifedipine and Octreotide  
Treatment in an Hyperinsulinemic  
Hypoglycemic Infant
Case Report
Introduction
Hyperinsulinemic hypoglycemia (HH) is the most common 
cause of recurrent or persistent hypoglycemia in infants (1). Its 
incidence is estimated to be 1 in 50 000 live births in outbred 
communities (2). Insufficient suppression of insulin secretion 
in the presence of recurrent serious hypoglycemia is the basic 
characteristic of this condition.
The most common mechanism underlying congenital 
hyperinsulinism is the dysfunction of the pancreatic ATP-
sensitive potassium (K-ATP) channel. This channel consists of 
two subunits: the sulfonylurea receptor (SUR1) subunit and 
the inwardly rectifying K+ subunit (KIR 6.2) (3). Usually, closure 
of the K-ATP channel initiates the depolarization in beta cell 
membrane leading to opening of calcium channels, increase 
in intracellular calcium concentrations and dysregulation of 
insulin release (4). The most common known cause of HH is 
mutations (ABCC8 and KCNJ11) in the genes encoding the 
subunits of K-ATP channel. These mutations result in absence 
or dysfunction of the K-ATP channels on the cell surface, 
which causes unregulated insulin release (4,5). Diazoxide is 
the first-line treatment of choice for HH, although the clinical 
effectiveness of this drug is variable (6). Glucagon and calcium-
channel blockers (nifedipine) can be considered in patients 
showing no response to diazoxide and octreotide. To date, a 
limited number of cases have been reported to have a good 
response to nifedipine. However, the underlying molecular 
pathophysiology of HH in these patients is not clear (5).
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Hyperinsulinemic hypoglycemia (HH) is the commonest cause of 
persistent hypoglycemia in the neonatal and infancy periods. Mutations 
in the ABCC8 and KCNJ11 genes, which encode subunits of the ATP-
sensitive potassium channel in the pancreatic beta cell, are identified in 
approximately 50% of these patients. The first-line drug in the treatment 
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show no response to diazoxide. Nifedipine, a calcium-channel blocker, 
has been shown to be an effective treatment in a small number of 
patients with diazoxide-unresponsive HH. We report a HH patient with 
a homozygous ABCC8 mutation (p.W1339X) who underwent a near-
total pancreatectomy at 2 months of age due to a lack of response to 
diazoxide and octreotide treatment. Severe hypoglycemic attacks 
continued following surgery, while the patient was being treated with 
octreotide. These attacks resolved when nifedipine was introduced. 
Whilst our patient responded well to nifedipine, the dosage could not 
be increased to 0.75 mg/kg/day due to development of hypotension, 
a reported side effect of this drug. Currently, our patient, now aged 4 
years, is receiving a combination of nifedipine and octreotide treatment. 
He is under good control and shows no side effects. In conclusion, 
nifedipine treatment can be started in patients with HH who show a 
poor response to diazoxide and octreotide treatment.  
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Here, we report a patient with a homozygous ABCC8 
nonsense mutation who responded well to a combination 
of nifedipine and octreotide treatment following a near-total 
pancreatectomy.
Case Report
Our patient was a male infant with a birth weight of 5000 
g, born at term by normal spontaneous vaginal delivery to a 
31-year-old healthy mother. The parents were first-degree 
cousins. On postpartum day 2, hypoglycemia (24 mg/dL) and 
hyperinsulinism (insulin level 15 mU/L) were detected. The 
patient was treated with 15-20 mg/kg/min IV dextrose infusion 
and 15 mg/kg/day of diazoxide. Steroid treatment (2 mg/kg/day) 
was also administered for a total of three days. Subsequently, 
during hypoglycemic episodes, octreotide (25 μg/kg/day) was 
introduced while diazoxide dosage was tapered down. The 
blood glucose levels remained at low levels and the patient 
underwent a near-total pancreatectomy at the age of 2 months. 
Hypoglycemic episodes were noted postoperatively and 
octreotide treatment (15 μg/kg/day) was re-started. As the 
hypoglycemia persisted despite an increase in the octreotide 
dose to 30 μg/kg/day (divided into 3 doses), a short-acting 
nifedipine was added (0.25 mg/kg/day (divided into 3 doses) to the 
treatment. Under close blood pressure and electrocardiography 
monitoring, the dose of nifedipine was increased to 0.5 
mg/kg/day (3 doses a day) and a good glycemic control was 
obtained, especially in postprandial blood glucose levels. The 
octreotide dose was tapered down to 5 μg/kg/day, but the 
treatment could not be discontinued. The dosage of nifedipine 
was subsequently increased to 0.75 mg/kg/day, but the dose 
was reverted to 0.5 mg/kg/day due to low systolic blood 
pressure. 
The patient has been receiving octreotide therapy (5 
μg/kg/day) for 4 years and nifedipine treatment (0.5 mg/kg/day) 
for 3 years. At present, he is in a state of good glycemic control 
with no severe hypoglycemic episodes. Glucose monitoring is 
made by a home glucometer, with routine venous hemoglobin 
A1c, insulin and glucose level measurements every three 
months. The patient is now four years old, his growth status 
is within normal limits (weight and height are both at the 
25th percentile) and no problem is noted in his neuromotor 
development. No drug side effects were observed and thyroid 
function tests remained within normal limits. Genetic investigation 
revealed a previously reported homozygous nonsense mutation 
(p.W1339X; c.4017G>A) in the ABCC8 gene (7). This result was 
consistent with the histological findings, which identified diffuse 
disease in the resected pancreas.
Discussion
Our patient responded well to nifedipine treatment. 
Nifedipine is a calcium-channel blocker and has been used 
in some patients with HH with success, although the vast 
majority of patients fail to show any response (8,9). The 
underlying molecular pathophysiology of HH is still unclear 
(5). Darendeliler et al (10) screened 13 HH patients for 
mutations in ABCC8 and KCNJ1. A genetic etiology could 
not be identified in 10 of these patients. Two out of three 
patients with ABCC8 mutations underwent pancreatectomy 
because of lack of response to treatment and hypoglycemia 
was reported to occur also post-operatively. Hyperinsulinism 
recurred after surgery in two patients. Treatment with either 
diazoxide or calcium-channel blocker proved to be effective 
in controlling hypoglycemia in the rest of these children. The 
authors concluded that mutations in the ABCC8 gene may 
not be predictive of the response to drugs. 
Another unclear point is nifedipine dose. Although some 
patients respond to a dose of 0.25 mg/kg/day, the dose need 
to be increased up to 2 mg/kg/day in others (8,9,11,12). 
This situation may be related to mutation type. In our case, 
there was no response to nifedipine in a dose of 0.25 
mg/kg/day, whereas a dramatic response was obtained with 0.5 
mg/kg/day. We could not increase the dosage due to 
hypotensive attacks which occurred at 0.75 mg/kg/day. 
Hypotension is a possible, yet uncommon side effect of 
nifedipine treatment in HH (5). Based on our experience 
with this patient, we suggest that the dose increase during 
nifedipine treatment for hyperinsulinism should be done with 
careful monitoring for undesirable effects.
Octreotide is a long-acting analogue of the natural 
hormone somatostatin, which has inhibitory effects on the 
release of insulin from pancreatic beta cells. It is used in the 
short- and long-term management of some patients with HH 
(13). Octreotide has been successfully used in the long-term 
management of some patients with HH in combination with 
frequent feeding (14). 
As far as we know, our patient is the first case to be 
treated with a combination of nifedipine and octreotide. 
Loechner et al (15) reported a patient diagnosed with 
congenital hyperinsulinism (due to KCNJ11 gene mutation), 
who had hypertension and was treated with octreotide and 
amlodipine (a calcium-channel blocker). They concluded that 
with this treatment, the baseline mean blood glucose level 
increased and was stabilized at a higher level than it would 
be by octreotide alone and that no episodes of blood glucose 
levels <60 mg/dL occurred with octreotide plus amlodipine 
(15). Voltage-gated T-type and L-type Ca2+ channels as well 
as Na+ channels participate in glucose-stimulated electrical 
activity and insulin secretion in pancreatic beta cells (16). 
Nifedipine is an L-type calcium-channel blocker. Octreotide 
inhibits Ca2+ entry into pancreatic beta cells via voltage-
operated Ca2+ channels (VOCCs) of the L-type, leading to 
suppression of insulin secretion (17). Moreover, octreotide 
hyperpolarizes insulinoma cells by activating (K-ATP) 
channel and thus lowers insulin secretion (18). Although 
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the mechanism is not clear, octreotide may have an additive 
effect on nifedipine treatment via effecting VOCCs and 
(K-ATP) channels. In our case, no side effect related to 
octreotide and nifedipine treatment was observed during the 
3-year follow-up period.
In conclusion, our case of diazoxide-resistant 
hyperinsulinism due to homozygous ABCC8 nonsense 
mutation showed a good response to a combined treatment 
of nifedipine and octreotide. Further studies are required to 
evaluate the nifedipine effect and its dose range in patients 
with HH.
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